Showing results (271-280 of 301) with videos related to
Sort By:
Pageof 31
EJNMMI Physics|October 27, 2015
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapyWietske Woliner-van der Weg, Rafke Schoffelen, Robert F Hobbs, et al.Frontiers in Medicine|December 8, 2015
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsCaroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 22, 2014
Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancerKristell L S Chatalic, Gerben M Franssen, Wytske M van Weerden, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trialFrançoise Kraeber-Bodéré, Alain Faivre-Chauvet, Ludovic Ferrer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie Ketas, et al.European Journal of Nuclear Medicine and Molecular Imaging|March 20, 2014
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancerRafke Schoffelen, Wietske Woliner-van der Weg, Eric P Visser, et al.British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC StudyCaroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid TumorsAlexander N Starodub, Allyson J Ocean, Manish A Shah, et al.Molecular Cancer Therapeutics|April 1, 2010
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenograftsRafke Schoffelen, Robert M Sharkey, David M Goldenberg, et al.Pageof 31